CPI 444

Drug Profile

CPI 444

Alternative Names: Adenosine A2A Receptor Antagonist - Corvus; CPI-444; Immune checkpoint inhibitor A; V 81444

Latest Information Update: 12 May 2017

Price : $50

At a glance

  • Originator Vernalis
  • Developer Corvus Pharmaceuticals; Genentech; Vernalis
  • Class Antineoplastics; Antiparkinsonians; Small molecules
  • Mechanism of Action Adenosine A2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cancer
  • No development reported Attention-deficit hyperactivity disorder; Parkinson's disease

Most Recent Events

  • 02 May 2017 Genentech and Corvus Pharmaceuticals plan a phase I/II trial for Non-small cell lung cancer (Second-line therapy or greater, Combination therapy)
  • 02 May 2017 Corvus Pharmaceuticals expands the clinical trial collaboration with Genentech for CPI 444 in Cancer
  • 04 Apr 2017 Interim efficacy and adverse events data from a phase I trial in Cancer presented at the 108th Annual Meeting of American Association for Cancer Research (AACR-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top